Other languages Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Equities

8SJ

CNE100003FF7

Delayed Deutsche Boerse AG Other stock markets 08:59:01 18/06/2024 BST			5-day change	1st Jan Change
1.4 ^EUR	+2.94%		+0.72%	-46.15%

06-13	Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	MT
06-12	Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	06-13
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	06-12
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results	06-12
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma	06-11
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	04-25
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	04-24
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	04-24
Junshi Biosciences Gets Nod to Register Toripalimab Injection	04-08
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	04-07
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	04-03
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	04-02
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	03-29
Junshi Bio's 2023 Loss Widens, Misses Estimates	02-26
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23
Junshi Biosciences Proposes Share Buyback	02-02
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	02-01
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	02-01
Shanghai Junshi Biosciences to Narrow Losses	01-31
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	01-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Equities

8SJ

CNE100003FF7

Other languages

Filters